Isomorphic Labs Raises $5 Billion to Advance AI-Designed Drugs
Demis Hassabis’ Isomorphic Labs raises $5 billion in a Series C co-led by Greenoaks and Sequoia, bringing its announced 2026 funding to $7.1 billion.
Isomorphic Labs combines AI, chemistry and biology to design medicines through proprietary research programs and pharmaceutical partnerships.
Isomorphic Labs is an AI-driven drug-discovery company combining machine learning with medicinal chemistry and biological research. Founded in 2021 by Demis Hassabis, it is headquartered in London. The business grew from the scientific advances associated with AlphaFold and was established to apply related ideas to the broader challenge of designing medicines.
Predicting a protein’s structure is one part of that challenge. A potential medicine must also interact with a biological target in a useful way, have suitable chemical properties and meet demanding safety requirements. Isomorphic Labs develops predictive and generative models intended to help researchers work through those connected questions, rather than treat structure prediction as a finished treatment.
Its Isomorphic Labs Drug Design Engine brings models and research tools together. Scientists can use the system to explore relationships between molecules, biological targets and desired properties, then prioritize candidates for further work. Computational predictions guide experiments, while laboratory evidence helps determine which ideas deserve to advance. The process combines expertise from AI research, chemistry, biology and drug development.
The company pursues internal discovery programs and partnerships with pharmaceutical businesses. Internal programs allow it to develop its own candidates, while collaborations apply its capabilities to agreed research objectives. Those partnerships can involve research funding, milestone payments and potential royalties, depending on their terms. The company’s proprietary research platform is not a general consumer application or an open software subscription sold to anyone.
Drug discovery remains distinct from clinical development. A candidate identified with AI still needs appropriate testing, clinical trials and regulatory review before it can become an approved medicine. The company’s technology is intended to improve the search and design process, not eliminate those requirements. Researchers therefore assess experimental evidence alongside model output throughout the work.
Isomorphic Labs is privately held, with Alphabet and external investors supporting its development. It brings together software and pharmaceutical disciplines within a single research business. Its long-term purpose is to build a repeatable method for designing medicines across diseases, while its commercial model combines ownership of internal programs with the economics of pharmaceutical collaborations.
Proprietary Isomorphic Labs Drug Design Engine
Research collaboration payments; development milestones; potential licensing and royalties
Demis Hassabis’ Isomorphic Labs raises $5 billion in a Series C co-led by Greenoaks and Sequoia, bringing its announced 2026 funding to $7.1 billion.